Literature DB >> 19086330

Clinical trial: percutaneous acetic acid injection vs. percutaneous ethanol injection for small hepatocellular carcinoma--a long-term follow-up study.

W L Tsai1, J S Cheng, K H Lai, C P Lin, G H Lo, P I Hsu, H C Yu, C K Lin, H H Chan, W C Chen, T A Chen, W L Li, H L Liang.   

Abstract

BACKGROUND: The long-term outcome of percutaneous acetic acid injection (PAI) and percutaneous ethanol injection (PEI) for treating small hepatocellular carcinoma (HCC) remains unclear. AIM: To compare the long-term outcome of PAI vs. PEI for treating small HCC.
METHODS: From July 1998 to July 2004, 125 patients with small HCC were enrolled. Seventy patients receiving PAI and 55 patients receiving PEI were enrolled. There were no significant differences in the clinical characteristics between the two groups. Tumour recurrence and survival rates were assessed.
RESULTS: Mean follow-up time was 43 months. The local recurrence rate and new tumour recurrence rate were similar between the PAI and PEI groups. The PAI group had significantly better survival than the PEI group (P = 0.027). Multivariate analysis revealed that PAI was the significant factor associated with overall survival [PAI vs. PEI, RR: 0.639, 95% CI: (0.419-1.975), P = 0.038]. The treatment sessions required to achieve complete tumour necrosis were significantly fewer in the PAI group than in the PEI group (2.4 +/- 1.0 vs. 2.9 +/- 1.3, P = 0.018).
CONCLUSION: Percutaneous acetic acid injection required fewer treatment sessions than PEI and provided better survival after long-term follow-up.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19086330     DOI: 10.1111/j.1365-2036.2008.03702.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  6 in total

Review 1.  Principles of and advances in percutaneous ablation.

Authors:  Muneeb Ahmed; Christopher L Brace; Fred T Lee; S Nahum Goldberg
Journal:  Radiology       Date:  2011-02       Impact factor: 11.105

Review 2.  Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma.

Authors:  Sebastian Weis; Annegret Franke; Thomas Berg; Joachim Mössner; Wolfgang E Fleig; Konrad Schoppmeyer
Journal:  Cochrane Database Syst Rev       Date:  2015-01-26

Review 3.  Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: a systematic review.

Authors:  Luis Calzadilla Bertot; Masaya Sato; Ryosuke Tateishi; Haruhiko Yoshida; Kazuhiko Koike
Journal:  Eur Radiol       Date:  2011-08-20       Impact factor: 5.315

4.  Irreversible electroporation therapy in the liver: longitudinal efficacy studies in a rat model of hepatocellular carcinoma.

Authors:  Yang Guo; Yue Zhang; Rachel Klein; Grace M Nijm; Alan V Sahakian; Reed A Omary; Guang-Yu Yang; Andrew C Larson
Journal:  Cancer Res       Date:  2010-02-02       Impact factor: 12.701

Review 5.  Image-guided percutaneous ablation therapies for local recurrences of thyroid tumors.

Authors:  C M Pacella; E Papini
Journal:  J Endocrinol Invest       Date:  2013-01       Impact factor: 4.256

6.  Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma.

Authors:  Wei-Lun Tsai; Kwok-Hung Lai; Huei-Lung Liang; Ping-I Hsu; Hoi-Hung Chan; Wen-Chi Chen; Hsien-Chung Yu; Feng-Woei Tsay; Huay-Min Wang; Hung-Chih Tsai; Jin-Shiung Cheng
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.